The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...